Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in Radioiodine-Refractory Differentiated Thyroid Cancer
NCT03602495Phase 3Terminated
- Sponsor
- Zelgen
- Start
- Aug 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in differentiated thyroid cancer (DTC) comparing Donafenib with Placebo (2 arms). Primary endpoint: Progression Free Survival up to 3 years. Started Aug 2018; status: terminated.
02
Drugs
donafenib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT03602495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602495.